300439 Medicalsystem Biotechnology
- 9.28
- +0.44+4.98%
Medicalsystem Biotechnology News
MedicalSystem Biotechnology Gets Nod to Register Two Devices in Zhejiang, China
Chinese in vitro diagnostic product manufacturer MedicalSystem Biotechnology (SHE:300439) obtained medical device registration certificates from the drug regulator of China's Zhejiang Province for two
Meikang Biotech (300439.SZ): 2023 equity distribution of 10 distributions of 1.34 yuan Equity Registration Date June 6
Gelonghui, May 31 | Meikang Biotech (300439.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 1.340000 in cash (tax included) for every 10 shares based on the company's current total share capital of 383,949,815 shares. The share registration date for this equity distribution is June 6, 2024, and the ex-dividend date is June 7, 2024.
MedicalSystem Biotechnology Gets Registration Certificates for Two Products
Chinese in vitro diagnostic product manufacturer MedicalSystem Biotechnology (SHE:300439) obtained a medical device registration certificate from the drug regulator of China's Zhejiang Province for tw
Does Medicalsystem Biotechnology (SZSE:300439) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Meikang Biotech (300439.SZ) received a medical device registration certificate
Meikang Biotech (300439.SZ) announced that the company recently obtained the “Medical...” issued by the Zhejiang Drug Administration
Meikang Biotech (300439.SZ): Net profit of 79.968 million yuan in the first quarter increased 10.76% year-on-year
Gelonghui, April 23 | Meikang Biotech (300439.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 482 million yuan, down 1.91% year on year; net profit attributable to shareholders of listed companies was 79.968 million yuan, up 10.76% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 64.749 million yuan, up 14.37% year on year; basic earnings per share were 0.21 yuan.
Meikang Biotech (300439.SZ): 2023 net profit of 257 million yuan, plans to distribute 10 to 1.34 yuan
Gelonghui, April 18 | Meikang Biotech (300439.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,886 billion yuan, a year-on-year decrease of 24.23%; net profit attributable to shareholders of listed companies was 255 million yuan, up 29.23% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 196 million yuan, up 14.89% year on year; basic income per share was 0.67 yuan; it plans to distribute a cash dividend of 1.34 yuan (tax included) to all shareholders for every 10 shares.
MedicalSystem Biotechnology Gets Nod to Market Fibrinogen Detection Kit
MedicalSystem Biotechnology (SHE:300439) received approval from the drug regulator of China's Zhejiang Province to market its fibrinogen detection kit, according to the company's filing published on t
Meikang Biology (300439.SZ): Suzhou Shengde passed the National High-tech Enterprise Certification
Gelonghui, March 21丨Meikang Biotech (300439.SZ) announced that Meikang Shengde Medical Technology (Suzhou) Co., Ltd. (“Suzhou Shengde”), a wholly-owned subsidiary of the company, recently received the “High-tech Enterprise Certificate” (certificate number: GR202332001909, date of issue: November 6, 2023, valid for three years).
Meikang Biotech (300439.SZ) obtained two medical device registration certificates
Meikang Biotech (300439.SZ) announced that the company obtained the “Medical Devices...” issued by the State Drug Administration
Investors Don't See Light At End Of Medicalsystem Biotechnology Co., Ltd's (SZSE:300439) Tunnel
With a price-to-earnings (or "P/E") ratio of 17.1x Medicalsystem Biotechnology Co., Ltd (SZSE:300439) may be sending bullish signals at the moment, given that almost half of all companies in China hav
Meikang Biology (300439.SZ): Hangzhou Shengde Medical Laboratory passed the re-accreditation of a national high-tech enterprise
Gelonghui, January 12, 丨 Meikang Biology (300439.SZ) announced that Hangzhou Meikang Shengde Medical Testing Laboratory Co., Ltd. (“Hangzhou Shengde Medical Laboratory”), a wholly-owned subsidiary of the company, recently received the “High-tech Enterprise Certificate” (certificate number: GR202333010219, date of issue: December 8, 2023, valid for three years).
Meikang Biotech (300439.SZ) has been re-certified as a national high-tech enterprise
Gelonghui, January 9丨Meikang Biotech (300439.SZ) announced that the company recently learned that the company has received the “High-tech Enterprise Certificate” (certificate number: GR202333100385) jointly issued by the Ningbo Municipal Bureau of Science and Technology, the Ningbo Municipal Finance Bureau, and the Ningbo Municipal Taxation Bureau of the State Administration of Taxation. (Date of issue: December 8, 2023, valid for three years).
Meikang Biotech (300439.SZ) granted restricted stocks for the first time to the incentive recipients of the 2023 Restricted Stock Incentive Program
Meikang Biotech (300439.SZ) issued an announcement that the company's 2023 restricted stock incentive plan stipulates the first time...
Meikang Biotech (300439.SZ): Currently, the company has not obtained any qualitative test reagent products related to influenza or pneumonia
Glonghui, December 12|Meikang Biotech (300439.SZ) said on the investor interactive platform that currently the company has not obtained any qualitative test reagent products related to influenza or pneumonia. The company's proven inflammation test kits such as C-reactive protein (CRP), serum amyloid A (SAA), procalcitonin (PCT), and interleukin-6 (IL-6) can be used for auxiliary diagnosis and monitoring of infected patients. The company's medical laboratory can provide testing services for influenza, respiratory infections, and mycoplasma pneumonia/chlamydia.
Meikang Biotech (300439.SZ) obtained a medical device registration certificate
Meikang Biotech (300439.SZ) announced that the company recently obtained “Medicine...” issued by the Zhejiang Drug Administration
Meikang Biotech (300439.SZ) plans to grant 2.17 million restricted shares
Meikang Biotech (300439.SZ) disclosed the 2023 Restricted Stock Incentive Plan (draft), and the company plans to grant...
Meikang Biotech (300439.SZ): The company did not participate in the Hi-Tech Fair
Gelonghui November 21丨Meikang Biotech (300439.SZ) stated on the investor interactive platform that the company did not participate in the Hi-Tech Fair. Recently, the company brought products such as fully automatic biochemical analyzers and fully automatic chemiluminescence analyzers to Germany to participate in the global medical exhibition MEDICA to actively expand overseas markets. The company's production and operation were all normal in the fourth quarter. Please pay attention to the company's regular reports for specific data.
Meikang Biotech (300439.SZ): Three products obtained medical device registration certificates
Meikang Biotech (300439.SZ) issued an announcement. The company and holding subsidiary Jiangxi Meikang Shengde Biotechnology Co., Ltd...
[BT Financial Report Instantaneous Analysis] Meikang Biotech's 2023 Quarterly Report: Net profit increased by 13.03%, net cash flow increased sharply by 68.67%
This financial report was announced on 2023-10-25 16:36:25 Meikang Biotech (stock code: 300439) is a company focusing on the R&D, production and sales of in vitro diagnostic products. The company's main products include in vitro diagnostic reagents, in vitro diagnostic instruments, and third-party medical diagnostic services. After 20 years of development, the company has the professional ability to develop and produce in vitro diagnostic instruments, reagents, calibrators and quality control products, and has a rich product line in the fields of biochemistry, chemiluminescence, mass spectrometry, VAP & VLP lipid subcomponents, molecular diagnosis, blood cells, POCT, urine, etc.
Analysis
Price Target
No Data
